Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Gains from Sales and Divestitures (2020 - 2023)

Serina Therapeutics (SER) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $3000.0 as the latest value for Q3 2023.

  • Quarterly Gains from Sales and Divestitures fell 70.0% to $3000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Sep 2023, down 70.0% year-over-year, with the annual reading at $13000.0 for FY2022, 8.33% up from the prior year.
  • Gains from Sales and Divestitures hit $3000.0 in Q3 2023 for Serina Therapeutics, roughly flat from $3000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $22000.0 in Q4 2020 to a low of $3000.0 in Q1 2020.
  • Historically, Gains from Sales and Divestitures has averaged $9181.8 across 4 years, with a median of $7000.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: rose 16.67% in 2022 and later tumbled 70.0% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $22000.0 in 2020, then crashed by 45.45% to $12000.0 in 2021, then rose by 8.33% to $13000.0 in 2022, then tumbled by 76.92% to $3000.0 in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for SER at $3000.0 in Q3 2023, $3000.0 in Q2 2023, and $3000.0 in Q1 2023.